Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|September 13, 2016

Catalent to Acquire Pharmatek

Catalent will acquire Pharmatek, a San Diego-based manufacturer of oral, injectable, and topical products.

On Sept. 13, 2016, Catalent Pharma Solutions announced its plans to acquire Pharmatek Laboratories, a California-based manufacturer of oral, injectable, and topical products. No financial terms of the agreement have been disclosed.

The acquisition of Pharmatek will add spray drying to Catalent’s portfolio of drug formulation and delivery technologies and expand their capability for handling highly potent compounds. Pharmatek offers a drug-development platform including formulation screening, formulation development, analytical services, and finished-dose-form manufacturing for clinical supply. The company also offers solutions for poorly soluble compounds, controlled release formulations, and facilities for potent compound handling.

Pharmatek’s San Diego facility contains two analytical and two formulation laboratories, four engineering rooms, and nine certified ISO Class 8 manufacturing suites. Catalent says they expect the transaction to close within the new few weeks and that the company will pay all cash in the acquisition.

Source: Catalent


Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.